NCT02976051

DAHANCA 33: Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic HNSCC

DAHANCA 33: Functional Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic Squamous Cell Carcinoma of the Head and Neck

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Danish Head and Neck Cancer Group · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Aim: To improve curability of radiotherapy in HNSCC patients identified by hypoxic FAZA-PET scanning

Detailed description

Prospective phase II study aiming to improve the outcome in hypoxic resistent patients identified by FAZA-PET. Inclusion: Patients must fulfill the following: Positive hypoxic FAZA-PET Scanning (as described in DAHANCA 24 - see citation) Stage III-IV, Squamous cell carcinoma of the larynx, pharynx or oral cavity (HPVneg (oropharynx) Indication for hyperfractionated accelerated radiotherapy with concommitant cis-platin and nimorazole

Conditions

• Locally Advanced Head and Neck Cancer
• Radiotherapy
• Hypoxic Radioresistance

Interventions

Type	Name	Description
RADIATION	HART-CN	HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole

Timeline

• Start date: 2017-01-01
• Primary completion: 2021-06-01
• Completion: 2022-12-01
• First posted: 2016-11-29
• Last updated: 2020-10-20

Locations

1 site across 1 country: Denmark